ATS View
한국어

Research & development Korean listed companies

Grouped by the industry code each company registered with DART. Sorted by latest quarterly operating profit.

한국어
Companies77
Operating profit−₩187bnlatest quarter, combined
Operating losses57
Average dividend yield3.2%2 payers

There are 77 KOSPI and KOSDAQ companies classified under research & development. Combined operating profit for the latest reported quarter across 66 of them was −₩187bn; 57 posted an operating loss and 5 swung to a profit from a loss a year earlier. The largest by quarterly operating profit were SK biopharmaceuticals, Alteogen and Aimed Bio. The median operating margin across the 36 with reported revenue was -58.1%. 2 paid a cash dividend, with an average reported yield of 3.2%.

Research & development companies

CompanyLatest quarter op. profitDividend yieldArticles 30dSignals
SK biopharmaceuticals KOSPI₩97.1bn
+57% YoY		–143Profit +50% Revenue +30% Revenue & profit growth Op. margin 20%+ Insider buying Supply contract
Alteogen KOSDAQ₩34.2bn0.1%55Turnaround Revenue +30% Op. margin 20%+
Aimed Bio KOSDAQ₩8.5bn
+280% YoY		–1Profit +50% Op. margin 20%+ Insider buying Clinical trial filing
Onconic Therapeutics KOSDAQ₩2.8bn
+151% YoY		–40Profit +50%
curacle KOSDAQ₩2.4bn–5Turnaround Op. margin 20%+
DreamCIS KOSDAQ₩2.3bn
+50% YoY		–2Revenue & profit growth
Genematrix KOSDAQ₩393m–2Turnaround
BioInfra KOSDAQ₩76m6.2%1Turnaround M&A / stake deal Delisting / halt risk Dividend cut High dividend
INGENIA Therapeutics KOSDAQ₩0m–1Turnaround Clinical trial filing
NeoImmuneTech KOSDAQ−₩3m–114 quarters of losses
Kolmar BioTech KOSDAQ−₩19m–1–
HLB Pharmaceutical KOSDAQ−₩31m–24Revenue +30% Share pledge
Biotoxtech KOSDAQ−₩182m–2Major holder adding Insider buying 4 quarters of losses
Naturalendo Tech KOSDAQ−₩194m–14 quarters of losses
Eone Diagnomics Genome Center KOSDAQ−₩716m–04 quarters of losses
Kainos Medicine KOSDAQ−₩1.1bn–14 quarters of losses
Cytogen KOSDAQ−₩1.2bn–64 quarters of losses
MOA Life Plus KOSDAQ−₩1.2bn–6Share pledge Major holder adding Dilution risk Private placement 4 quarters of losses
IMBdx KOSDAQ−₩1.4bn–04 quarters of losses
3billion KOSDAQ−₩1.7bn–214 quarters of losses
Penetrium Bioscience KOSDAQ−₩1.9bn–19Share pledge Major holder adding 4 quarters of losses
HLB bioStep KOSDAQ−₩1.9bn–3–
KoBioLabs KOSDAQ−₩2.0bn–04 quarters of losses
Helixmith KOSDAQ−₩2.2bn–24 quarters of losses
IntoCell KOSDAQ−₩2.2bn–14 quarters of losses
Pharos iBio KOSDAQ−₩2.3bn–54 quarters of losses
Aribiolab KOSDAQ−₩2.5bn–15Share pledge Dilution risk Private placement Control change 4 quarters of losses
Inventera KOSDAQ−₩2.5bn–10Clinical trial filing
Cellid KOSDAQ−₩2.5bn–30Dilution risk Private placement 4 quarters of losses
Genomictree KOSDAQ−₩2.6bn–64 quarters of losses
IMBiologics KOSDAQ−₩2.7bn–4–
Oncocross KOSDAQ−₩2.7bn–24 quarters of losses
HEM Pharma KOSDAQ−₩2.9bn–0Supply contract 4 quarters of losses
AprilBio KOSDAQ−₩2.9bn–9Insider buying 4 quarters of losses
Quratis KOSDAQ−₩3.0bn–54 quarters of losses
Choolip & Sciences KOSDAQ−₩3.1bn–04 quarters of losses
Aptabio Therapeutics KOSDAQ−₩3.6bn–04 quarters of losses
MedPacto KOSDAQ−₩3.6bn–4Clinical trial filing 4 quarters of losses
Y-Biologics KOSDAQ−₩3.8bn–04 quarters of losses
EyeGene KOSDAQ−₩3.9bn–04 quarters of losses
Proteina KOSDAQ−₩4.0bn–54 quarters of losses
JS Link KOSDAQ−₩4.2bn–4Supply contract Asset deal 4 quarters of losses
TiumBio KOSDAQ−₩4.2bn–5M&A / stake deal 4 quarters of losses
ImmuneOncia Therapeutics KOSDAQ−₩4.3bn–14Clinical trial filing 4 quarters of losses
Abion KOSDAQ−₩4.3bn–6Clinical trial filing 4 quarters of losses
Organoidsciences KOSDAQ−₩4.4bn–44 quarters of losses
Mezzion Pharma KOSDAQ−₩4.5bn–24 quarters of losses
Geninus KOSDAQ−₩4.6bn–14 quarters of losses
Kanaph Therapeutics KOSDAQ−₩4.7bn–5–
Vaxcell-Bio Therapeutics KOSDAQ−₩5.0bn–224 quarters of losses
CG Invites KOSDAQ−₩5.9bn–8Supply contract M&A / stake deal 4 quarters of losses
SillaJen KOSDAQ−₩6.2bn–12Clinical trial filing 4 quarters of losses
CJ Bioscience KOSDAQ−₩6.4bn–04 quarters of losses
Dt&cro KOSDAQ−₩6.6bn–6Litigation
Rznomics KOSDAQ−₩6.9bn
-324% YoY		–12Swung to loss 4 quarters of losses
LabGenomics KOSDAQ−₩6.9bn–12Insider selling 4 quarters of losses
ToolGen KOSDAQ−₩6.9bn–34 quarters of losses
Curocell KOSDAQ−₩9.7bn–1Insider selling 4 quarters of losses
D&D Pharmatech KOSDAQ−₩9.9bn–54 quarters of losses
Inventage Lab KOSDAQ−₩10.3bn–154 quarters of losses
Genexine KOSDAQ−₩10.5bn–34 quarters of losses
Qurient KOSDAQ−₩12.8bn–264 quarters of losses
OliX Pharmaceuticals KOSDAQ−₩14.0bn–20Clinical trial filing 4 quarters of losses
GI Innovation KOSDAQ−₩14.4bn–04 quarters of losses
Voronoi KOSDAQ−₩29.3bn–20Clinical trial filing 4 quarters of losses
LigaChem Biosciences KOSDAQ−₩72.0bn–144 quarters of losses
Prestige BioPharma KOSPI––124 quarters of losses
Cronex KONEX––0–
Invites Biocore KONEX––0–
NovMetaPharma KONEX––0–
Medizen Humancare KONEX––0–
AngioLab KONEX––0Insider buying
ProGen KONEX––0–
ViGenCell KOSDAQ––04 quarters of losses
Moogene Medi KONEX––0–
Future Medicine KONEX––0Delisting / halt risk
Epi Biotech KONEX––0–

Industry codes are the primary business each company registered with DART and may not reflect its full business mix. Figures come from DART filings; prices are not included. Not investment advice.